CIK 0001714899
- Large accelerated filer
Denali Therapeutics Inc.
Sign in to watch- Ticker
- DNLI
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 463872213
- Phone
- +1 650-866-8547
- Business address
- 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale President and CEO sold 2,719 shares at $37.55 ($102,104)
- 4 Open-market sale COO and Secretary sold 1,423 shares at $37.10 ($52,800)
- 4 Open-market sale Chief Medical Officer sold 1,423 shares at $37.10 ($52,791)
- 4 Grant or award Director acquired 6,869 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award Director acquired 627 shares (grant or award)
- 4 Open-market sale President and CEO sold 5,007 shares at $44.78 ($224,213)
- 4 Open-market sale CFO and Treasurer sold 2,225 shares at $44.75 ($99,569)
- 4 Open-market sale Chief Medical Officer sold 2,845 shares at $44.78 ($127,399)
- 4 Open-market sale COO and Secretary sold 2,846 shares at $44.77 ($127,415)
- 4 Grant or award COO and Secretary acquired 31,000 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 31,000 shares (grant or award)
- 4 Grant or award President and CEO acquired 62,000 shares (grant or award)
- 4 Grant or award CFO and Treasurer acquired 31,000 shares (grant or award)
- 4 Open-market sale Director sold 63,131 shares at an average $44.43 ($2,805,197)
- 4 Open-market sale COO and Secretary sold 10,000 shares at an average $42.27 ($422,736)
- 4 Open-market sale Chief Medical Officer sold 1,476 shares at $42.52 ($62,760)
- 4 Open-market sale President and CEO sold 18,333 shares at an average $44.92 ($823,581)
- 4 Open-market sale Director sold 1,666 shares at an average $52.81 ($87,983)
- 4 Open-market sale COO and Secretary sold 10,000 shares at an average $52.84 ($528,404)
Page 10 of 22 · 436 filings